Loading...
Pharming Group N.V.
PHARM.AS•EURONEXT
Healthcare
Biotechnology
€0.86
€-0.00(-0.46%)
Pharming Group N.V. (PHARM.AS) Financial Performance & Income Statement Overview
Review Pharming Group N.V.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
16.95%
↑ 16.95%
Operating Income Growth
-70.55%
↓ 70.55%
Net Income Growth
-0.91%
↓ 0.91%
Operating Cash Flow Growth
90.00%
↑ 90.00%
Operating Margin
-0.07%
↓ 0.07%
Gross Margin
88.98%
↑ 88.98%
Net Profit Margin
-4.39%
↓ 4.39%
ROE
-6.47%
↓ 6.47%
ROIC
-0.07%
↓ 0.07%
Pharming Group N.V. (PHARM.AS) Income Statement & Financial Overview
Review Pharming Group N.V.'s (PHARM.AS) income statement with detailed quarterly and annual figures.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $75.06M | $74.03M | $55.46M | $81.87M |
| Cost of Revenue | $6.84M | $7.99M | $8.37M | $14.78M |
| Gross Profit | $68.22M | $66.04M | $47.09M | $67.09M |
| Gross Profit Ratio | $0.91 | $0.89 | $0.85 | $0.82 |
| R&D Expenses | $20.72M | $21.58M | $18.48M | $11.70M |
| SG&A Expenses | $43.98M | $48.45M | $45.23M | $54.79M |
| Operating Expenses | $63.92M | $70.03M | $63.71M | $66.49M |
| Total Costs & Expenses | $70.74M | $78.03M | $72.07M | $81.26M |
| Interest Income | $825000.00 | $920000.00 | $1.78M | $1.61M |
| Interest Expense | $3.00M | $1.97M | $1.56M | $1.34M |
| Depreciation & Amortization | $2.74M | -$293000.00 | $5.92M | $7.55M |
| EBITDA | $7.25M | -$4.28M | -$9.63M | $6.87M |
| EBITDA Ratio | $0.10 | -$0.06 | -$0.19 | $0.10 |
| Operating Income | $4.11M | -$4.00M | -$16.62M | $604930.00 |
| Operating Income Ratio | $0.05 | -$0.05 | -$0.30 | $0.007 |
| Other Income/Expenses (Net) | -$2.59M | $3.06M | $260823.00 | -$3.10M |
| Income Before Tax | $1.51M | $299719.00 | -$16.05M | -$2.72M |
| Income Before Tax Ratio | $0.02 | $0.004 | -$0.29 | -$0.03 |
| Income Tax Expense | $2.55M | $1.10M | -$4.17M | $705747.00 |
| Net Income | -$1.03M | -$1.20M | -$12.42M | -$2.72M |
| Net Income Ratio | -$0.01 | -$0.02 | -$0.22 | -$0.03 |
| EPS | -$0.002 | -$0.001 | -$0.02 | -$0.003 |
| Diluted EPS | -$0.002 | -$0.001 | -$0.02 | -$0.003 |
| Weighted Avg Shares Outstanding | $646.25M | $847.94M | $838.84M | $838.84M |
| Weighted Avg Shares Outstanding (Diluted) | $646.25M | $847.94M | $838.84M | $838.84M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan